Aridis Pharmaceuticals’ $26 Million Initial Public Offering

Sheppard Mullin represented Aridis Pharmaceuticals on the deal Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using…

This content is for members only.
Login to Read More Join Now
Avatar

Author: Ambrogio Visconti

This content is for members only.
Login to Read More Join Now